GCET2 CRISPR Activation Plasmid (h): sc-418185-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GCET2 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- GCET2 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by GCET2 CRISPR Activation Plasmid (h) and GCET2 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the GCSAM transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GCET2 CRISPR Activation Plasmid (h) | sc-418185-ACT | 20 µg | $397.00 |
GCSAM (also known as GCET2) is a lymphocyte-associated adaptor protein enriched in germinal center B cells and other hematopoietic lineages, where it supports signaling outputs linked to B-cell receptor engagement and cytoskeletal remodeling. By coupling receptor-proximal cues to actin dynamics and migratory behavior, GCET2 has been implicated in regulation of immune cell activation, adhesion, and trafficking within lymphoid microenvironments. Altered expression patterns have been reported in B-cell malignancy contexts, making the gene a useful marker and mechanistic node for studying pathways that shape germinal center biology and malignant transformation. Functional interrogation of GCSAM helps connect transcriptional states with changes in signaling amplitude, cellular motility, and immune microenvironment interactions.
GCET2 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous GCSAM expression without altering the underlying DNA sequence.
GCET2 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the GCSAM locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the GCSAM transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous GCET2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native GCSAM locus and enabling the study of GCET2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of GCET2 pathway restoration in tumor cells with silenced or reduced GCSAM expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.